-
ALSO READ
Dishman Carbogen Amcis to consider NCD issuance
Dishman Carbogen spurts after Q3 PAT rises 33% YoY
Dishman Carbogen Amcis Ltd leads gainers in 'A' group
Dishman Carbogen Amcis reports consolidated net loss of Rs 10.05 crore in the September 2022 quarter
Board of Dishman Carbogen Amcis approves NCD issuance up to Rs 100 cr
-
Dishman Carbogen Amcis jumped 6.81% to Rs 127.90 after the company said that its board will consider fund raising through issuance of non-convertible debentures (NCDs) on Friday, 10 March 2023.
The pharma company said that the NCDs will be issued by way of private placement, subject to such regulatory or statutory approvals as may be required.Dishman Carbogen Amcis is a fully integrated CRAMS (contract research & manufacturing) company. The company has global presence with development and manufacturing sites in Switzerland, UK, France, Netherlands, India, and China.
The company's consolidated net profit rose 32.7% to Rs 46.96 crore on 13.8% increase in revenue from operations to Rs 639.79 crore in Q3 December 2022 over Q3 December 2021.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Subscribe to Business Standard Premium
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.
Download the Business Standard App for latest Business News and Market News .
RECOMMENDED FOR YOU